Pfizer (PFE)
(Delayed Data from NYSE)
$29.75 USD
-0.08 (-0.27%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $29.78 +0.03 (0.10%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PFE 29.75 -0.08(-0.27%)
Will PFE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PFE
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
Lilly Gets FDA Approval for Eczema Drug Ebglyss
Other News for PFE
10 Health Care Stocks With Whale Alerts In Today's Session
BlackRock Advantage Large Cap Value Fund Q2 2024 Commentary
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts